Chronic opioid exposure is known to produce neuroplastic changes in animals; however, it is not known if opioids used over short periods of time and at analgesic dosages can similarly change brain structure in humans. In this longitudinal, magnetic resonance imaging study, 10 individuals with chronic low back pain were administered oral morphine daily for 1 month. High-resolution anatomical images of the brain were acquired immediately before and after the morphine administration period. Regional changes in gray matter volume were assessed on the whole brain using tensor-based morphometry, and those significant regional changes were then independently tested for correlation with morphine dosage. Thirteen regions evidenced significant volumetric change, and degree of change in several of the regions was correlated with morphine dosage. Dosage-correlated volumetric decrease was observed primarily in the right amygdala. Dosage-correlated volumetric increase was seen in the right hypothalamus, left inferior frontal gyrus, right ventral posterior cingulate, and right caudal pons. Follow-up scans that were conducted an average of 4.7 months after cessation of opioids demonstrated many of the morphine-induced changes to be persistent. In a separate study, 9 individuals consuming blinded placebo capsules for 6 weeks evidenced no significant morphologic changes over time. The results add to a growing body of literature showing that opioid exposure causes structural and functional changes in reward-and affect-processing circuitry. Morphologic changes occur rapidly in humans during new exposure to prescription opioid analgesics. Further research is needed to determine the clinical impact of those opioid-induced gray matter changes. Ó
Introduction
Opioid prescriptions have increased markedly in recent years, driven by a greater reliance on the potent analgesics for the treatment of chronic pain [18, 34] . Opioid analgesics are second only to lipid regulators as the most dispensed drug class in the United States [28] . Hydrocodone, a moderately powerful opioid, was dispensed in the United States more than any other drug in 2008 -over 128 million times [27] . As opioid use rises, it becomes increasingly important that we better understand the neurological and behavioral effects of those drugs -especially given the known risks of opioid dependence, addiction, cognitive impairment, and hyperalgesia [7, 13, 14, 29, 43, 44] .
Recently, Upadhyay and colleagues [55] demonstrated that prescription opioid-dependent patients evidenced a specific morphologic abnormality in the neural reward-processing network. In their cross-sectional study of 10 dependent individuals and 10 age-matched controls, the researchers found decreased gray matter volume in the bilateral amygdala. The amygdala is a key reward-modulating structure that is known to underlie opioidrelated addiction, dependence, and tolerance Despite interesting preliminary evidence suggesting opioid-induced brain changes in humans, significant gaps in the literature remain. First, existing cross-sectional studies do not allow us to say with certainty that the observed brain abnormalities are a direct consequence of opioid administration (as opposed to a neural predisposition for opioid dependency). Second, current human data are based on opioid-dependent individuals, and may not accurately reflect cases in which the opioids are legitimately prescribed for chronic pain, and taken exactly as prescribed. To fill those gaps in the scientific literature, we conducted the first longitudinal study of prescription opioid effects on the human brain. The primary purpose of this magnetic resonance imaging (MRI) pilot study was to determine if any measurable changes in human brain
